Brief: Crossject confirms development plan for Zeneo Sumatriptan
16/07/2015 16:35
July 16 (Reuters) - Crossject SA ALCJ.PA :
* Confirms correct execution of clinic and regulatory
development plan of Zeneo Sumatriptan
* The calendar of bioequivalence study of Zeneo Sumatriptan
is confirmed and expected in second half of 2015
Source text for Eikon: ID:nHUG3XhnbH
Further company coverage: ALCJ.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 6983920;))
Recent news on Crossject SA
See all newsBrief: Crossject Says Expects To File For EUA Early Next Year For Epilepsy Rescue Therapy Zepizure
Brief: Crossject Signs A Geographic Extension Of Zepizure Commercialization Agreement In Europe
Brief: Crossject FY Operating Income Up At EUR 12.82 Mln
Brief: Crossject Announces Contract Of Up To $155 Mln With BARDA
Brief: Crossject Engages Syneos Health For U.S. Commercial Launch Of Zepizure